GuruFocus·Jul 21, 2026
Are DXLG, LAB, FHB, RLYB Obtaining Fair Deals for their Shareholders?Are DXLG, LAB, FHB, RLYB Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, July 21, 2026
Rallybio remains a pre-commercial biotechnology entity whose valuation is almost entirely tethered to binary clinical trial outcomes rather than recurring revenue, which has fluctuated between $38,000 and $299,000 over the last ten quarters. The company's reli...
Price trend, volume and key moving averages
Trailing total returns as of 10/3/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 6, 2026 | -$1.09+14.8% vs -$1.28 | — vs $216,480 |
Q2 2026 May 13, 2026 | -$1.46-21.7% vs -$1.20 | $212,000+0.0% vs $212,000 |
Q2 2026 Mar 12, 2026 | -$1.11+10.5% vs -$1.24 | $222,000+122.0% vs $100,000 |
Q4 2025 Nov 6, 2025 | -$0.14+44.0% vs -$0.25 | $212,000+218.0% vs $66,667 |
Are DXLG, LAB, FHB, RLYB Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, July 21, 2026
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
Benchmark RLYB against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Rallybio Corporation (RLYB)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $17.08 | $90.64M | -10.74 | 34.91% | -1046.39% | -15.01% | — | |
| $33.62 | $6.94B | -12.14 | — | -7585.86% | -69.59% | — | |
| $295.51 | $8.24B | -21.92 | -100% | — | -34.15% | — | |
| $107.39 | $8.83B | -29.10 | -16.72% | -285.41% | -21.5% | — | |
| $25.16 | $3.15B | -193.54 | 91.34% | 6.15% | 15.05% | — | |
| $0.81 | $12.35M | -0.13 | — | — | -1270.11% | — |
Rallybio Corporation (RLYB) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Rallybio Corporation (RLYB) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jun 1, 2026·SEC
May 4, 2026·SEC
Mar 31, 2026·SEC
Get notified when RLYB posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Rallybio Corporation (RLYB) stock FAQ — growth, dividends, profitability & financials explained
Rallybio Corporation (RLYB) reported $0.6M in revenue for fiscal year 2025.
Rallybio Corporation (RLYB) grew revenue by 34.9% over the past year. This is strong growth.
Yes, Rallybio Corporation (RLYB) is profitable, generating $45.6M in net income for fiscal year 2025 (-1046.4% net margin).
Rallybio Corporation (RLYB) has a return on equity (ROE) of -15.0%. Negative ROE indicates the company is unprofitable.
Rallybio Corporation (RLYB) generated $26.3M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
